NMDA neurotransmission as a critical mediator of borderline personality disorder

Journal of Psychiatry and Neuroscience

Volumn 32, Issue 2, 2007, Pages 103-115

  Grosjean, Bernadette ^a   Tsai, Guochuan E ^b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b NONE

Author keywords

Borderline personality disorder; Cognitive dysfunction; NMDA neurotransmission

Indexed keywords

GLYCINE RECEPTOR ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT;

ADAPTATION; BORDERLINE STATE; COGNITIVE DEFECT; DISSOCIATIVE DISORDER; DRUG MECHANISM; ENVIRONMENTAL FACTOR; HUMAN; NEUROTRANSMISSION; NOCICEPTION; NONHUMAN; PATIENT EDUCATION; PSYCHOSIS; PSYCHOTHERAPY; REVIEW; SOCIAL SUPPORT;

EID: 34247146773     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (132)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington: The Association; 1994.
2. Zanarini MC. Borderline personality disorders. Boca Raton: Taylor & Francis; 2005:19-40.
3. Gunderson JG. Borderline personality disorder: a clinical guide. 1st ed. Washington, DC: American Psychiatric Press; 2001:1-33.
4. Torgersen S. Epidemiology. In Oldham JM, Skodol AE, Bender DS eds. The American Psychiatric Publishing textbook of personality disorders. 1st ed. Washington, DC: American Psychiatric Pub; 2005:129-141.
5. Zanarini MC, Frankenburg FR, Vujanovic AA, et al. Axis II comorbidity of borderline personality disorder: description of 6-year course and prediction to time-to-remission. Acta Psychiatr Scand 2004;110:416-20.
6. Lieb K, Zanarini MC, Schmahl C, et al. Borderline personality disorder. Lancet 2004;364:453-61.
7. Zanarini MC, Ruser T, Frankenburg FR, et al. The dissociative experiences of borderline patients. Compr Psychiatry 2000;41:223-7.
8. Kernberg O. Borderline personality organization. J Am Psychoanal Assoc 1967;15:641-85.
9. Linehan M. Cognitive-behavioral treatment of borderline personality disorder. New York: Guilford Press; 1993:558 p.
10. Ruocco AC. The neuropsychology of borderline personality disorder: a meta-analysis and review. Psychiatry Res 2005;137:191-202.
11. Posner MI, Rothbart MK, Vizueta N, et al. An approach to the psychobiology of personality disorders. Dev Psychopathol 2003;15: 1093-106.
12. Tebartz van Elst L, Hesslinger B, Thiel T, et al. Frontolimbic brain abnormalities in patients with borderline personality disorder: a volumetric magnetic resonance imaging study. Biol Psychiatry 2003;54:163-71.
13. Juengling FD, Schmahl C, Hesslinger B, et al. Positron emission tomography in female patients with borderline personality disorder. J Psychiatr Res 2003;37:109-15.
14. Hazlett EA, New AS, Newmark R, et al. Reduced Anterior and Posterior Cingulate Gray Matter in Borderline Personality Disorder. Biol Psychiatry. 2005.
15. Donegan NH, Sanislow CA, Blumberg HP, et al. Amygdala hyperreactivity in borderline personality disorder: implications for emotional dysregulation. Biol Psychiatry 2003;54:1284-93.
16. Gurvits IG, Koenigsberg HW, Siever LJ. Neurotransmitter dysfunction in patients with borderline personality disorder. Psychiatr Clin North Am 2000;23:27-40.
17. Friedel RO. Dopamine dysfunction in borderline personality disorder: a hypothesis. Neuropsychopharmacology 2004;29:1029-39.
18. Rinne T, de Kloet ER, Wouters L, et al. Hyperresponsiveness of hypothalamic-pituitary-adrenal axis to combined dexamethasone / corticotropin-releasing hormone challenge in female borderline personality disorder subjects with a history of sustained childhood abuse. Biol Psychiatry 2002;52:1102-12.
19. Coccaro EF, Siever LJ, Klar HM, et al. Serotonergic studies in patients with affective and personality disorders. Correlates with suicidal and impulsive aggressive behavior. Arch Gen Psychiatry 1989;46:587-99.
20. Watanabe M, Inoue Y, Sakimura K, et al. Distinct spatio-temporal distributions of the NMDA receptor channel subunit mRNAs in the brain. Ann NY Acad Sci 1993;707:463-6.
21. Perez-Otano I, Ehlers MD. Homeostatic plasticity and NMDA receptor trafficking. Trends Neurosci 2005;28:229-38.
22. Figueroa E, Silk KR. Biological implications of childhood sexual abuse in borderline personality disorder. J Personal Disord 1997; 11:71-92.
23. Bateman A, Fonagy P. Psychotherapy for borderline personality disorder: mentalization-based treatment. Oxford; New York: Oxford University Press; 2004: 381 p.
24. Posner MI, Rothbart MK, Vizueta N, et al. Attentional mechanisms of borderline personality disorder. Proc Natl Acad Sci U S A 2002;99:16366-70.
25. Milham MP, Banich MT. Anterior cingulate cortex: an fMRI analysis of conflict specificity and functional differentiation. Hum Brain Mapp 2005;25:328-35.
26. Fan J, Fossella J, Sommer T, et al. Mapping the genetic variation of executive attention onto brain activity. Proc Natl Acad Sci U S A 2003;100:7406-11.
27. Driessen M, Herrmann J, Stahl K, et al. Magnetic resonance imaging volumes of the hippocampus and the amygdala in women with borderline personality disorder and early traumatization. Arch Gen Psychiatry 2000;57:1115-22.
28. Vyas A, Mitra R, Shankaranarayana Rao BS, et al. Chronic stress induces contrasting patterns of dendritic remodeling in hippocampal and amygdaloid neurons. J Neurosci 2002;22:6810-8.
29. Rusch N, van Elst LT, Ludaescher P, et al. A voxel-based morphometric MRI study in female patients with borderline personality disorder. Neuroimage 2003;20:385-92.
30. Birbaumer N, Veit R, Lotze M, et al. Deficient fear conditioning in psychopathy: a functional magnetic resonance imaging study. Arch Gen Psychiatry 2005;62:799-805.
31. Lange C, Kracht L, Herholz K, et al. Reduced glucose metabolism in temporo-parietal cortices of women with borderline personality disorder. Psychiatry Res 2005;139:115-26.
32. Lobaugh NJ, Gibson E, Taylor MJ. Children recruit distinct neural systems for implicit emotional face processing. Neuroreport 2006;17:215-9.
33. Winters BD, Bussey TJ. Glutamate receptors in perirhinal cortex mediate encoding, retrieval, and consolidation of object recognition memory. J Neurosci 2005;25:4243-51.
34. Rizzolatti G, Fadiga L. Grasping objects and grasping action meanings: the dual role of monkey rostroventral premotor cortex (area F5). [discussion 95-103]. Novartis Found Symp 1998;218:81-95.
35. Iacoboni M, Molnar-Szakacs I, Gallese V, et al. G. Grasping the intentions of others with one's own mirror neuron system. PLoS Biol 2005;3:e79.
36. Tsukada H, Nishiyama S, Fukumoto D, et al. Chronic NMDA antagonism impairs working memory, decreases extracellular dopamine, and increases D1 receptor binding in prefrontal cortex of conscious monkeys. Neuropsychopharmacology 2005;30:1861-9.
37. Homayoun H, Stefani MR, Adams BW, et al. Functional Interaction Between NMDA and mGlu5 Receptors: Effects on Working Memory, Instrumental Learning, Motor Behaviors, and Dopamine Release. Neuropsychopharmacology 2004;29:1259-69.
38. Ellis KA, Nathan PJ. The pharmacology of human working memory. Int J Neuropsychopharmacol 2001;4:299-313.
39. Stefani MR, Moghaddam B. Transient N-methyl-D-aspartate receptor blockade in early development causes lasting cognitive deficits relevant to schizophrenia. Biol Psychiatry 2005;57:433-6.
40. Rumpel S, LeDoux J, Zador A, et al. Postsynaptic receptor trafficking underlying a form of associative learning. Science 2005;308:83-8.
41. Lanius RA, Williamson PC, Bluhm RL, et al. Functional connectivity of dissociative responses in posttraumatic stress disorder: a functional magnetic resonance imaging investigation. Biol Psychiatry 2005;57:873-84.
42. Lahti AC, Holcomb HH, Medoff DR, et al. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 1995;6:869-72.
43. Steriade M. Corticothalamic resonance, states of vigilance and mentation. Neuroscience 2000;101:243-76.
44. Chambers RA, Bremner JD, Moghaddam B, et al. Glutamate and post-traumatic stress disorder: toward a psychobiology of dissociation. Semin Clin Neuropsychiatry 1999;4:274-81.
45. Frith U, Frith CD. Development and neurophysiology of mentalizing. Philos Trans R Soc Lond B Biol Sci 2003;358:459-73.
46. Kernberg OF. Psychodynamic psychotherapy of borderline patients. New York: Basic Books; 1989:210 p.
47. Gillespie CF, Ressler KJ. Emotional learning and glutamate: translational perspectives. CNS Spectr 2005;10:831-9.
48. Ressler KJ, Rothbaum BO, Tannenbaum L, et al. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 2004;61:1136-44.
49. Hofmann SG, Meuret AE, Smits JA, et al. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry 2006;63:298-304.
50. Goodman M, New A, Siever L. Trauma, genes, and the neurobiology of personality disorders. Ann NY Acad Sci 2004;1032:104-16.
51. Battle CL, Shea MT, Johnson DM, et al. Childhood maltreatment associated with adult personality disorders: findings from the Collaborative Longitudinal Personality Disorders Study. J Personal Disord 2004;18:193-211.
52. Johnson JG, Cohen P, Brown J, et al. Childhood maltreatment increases risk for personality disorders during early adulthood. Arch Gen Psychiatry 1999;56:600-6.
53. Bandelow B, Krause J, Wedekind D, et al. Early traumatic life events, parental attitudes, family history, and birth risk factors in patients with borderline personality disorder and healthy controls. Psychiatry Res 2005;134:169-79.
54. Fonagy P, Target M, Gergely G. Attachment and borderline personality disorder. A theory and some evidence. [vii-viii.]. Psychiatr Clin North Am 2000;23:103-22.
55. Fertuck EA, Lenzenweger MF, Clarkin JF. The association between attentional and executive controls in the expression of borderline personality disorder features: a preliminary study. Psychopathology 2005;38:75-81.
56. Wagner AW, Linehan MM. Facial expression recognition ability among women with borderline personality disorder: implications for emotion regulation? J Personal Disord 1999;13:329-44.
57. Camras L, Roibordy S, Hill J, et al. Maternal facial behavior and the recognition and production of emotional expressions by maltreated and nonmaltreated children. Dev Psychol 1990; 26:304-12.
58. Blair RJ, Cipolotti L. Impaired social response reversal. A case of 'acquired sociopathy'. Brain 2000;123:1122-41.
59. Fonagy P. Attachment and borderline personality disorder. [discussion 1175-87]. J Am Psychoanal Assoc 2000;48:1129-46.
60. Fonagy P, Target M. Attachment and reflective function: their role in self-organization. Dev Psychopathol 1997;9:679-700.
61. Sapolsky RM. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry 2000;57:925-35.
62. McEwen BS. Stress and hippocampal plasticity. Annu Rev Neurosci 1999;22:105-22.
63. Bredy TW, Zhang TY, Grant RJ, et al. Peripubertal environmental enrichment reverses the effects of maternal care on hippocampal development and glutamate receptor subunit expression. Eur J Neurosci 2004;20:1355-62.
64. Burgess N, Maguire EA, O'Keefe J. The human hippocampus and spatial and episodic memory. Neuron 2002;35:625-41.
65. Rosen JB, Donley MP. Animal studies of amygdala function in fear and uncertainty: Relevance to human research. Biol Psychol. 2006.
66. Debiec J, Doyere V, Nader K, et al. Directly reactivated, but not indirectly reactivated, memories undergo reconsolidation in the amygdala. Proc Natl Acad Sci U S A 2006;103:3428-33.
67. Johnson LR, Farb C, Morrison JH, et al. Localization of glucocorticoid receptors at postsynaptic membranes in the lateral amygdala. Neuroscience 2005;136:289-99.
68. Herpertz SC, Dietrich TM, Wenning B, et al. Evidence of abnormal amygdala functioning in borderline personality disorder: a functional MRI study. Biol Psychiatry 2001;50:292-8.
69. Gallagher HL, Frith CD. Functional imaging of 'theory of mind'. Trends Cogn Sci 2003;7:77-83.
70. Brune M. "Theory of mind" in schizophrenia: a review of the literature. Schizophr Bull 2005;31:21-42.
71. Bora E, Vahip S, Gonul AS, et al. A. Evidence for theory of mind deficits in euthymic patients with bipolar disorder. Acta Psychiatr Scand 2005;112:110-6.
72. Frith U. Mind blindness and the brain in autism. Neuron 2001;32: 969-79.
73. Rowe AD, Bullock PR, Polkey CE, et al. "Theory of mind" impairments and their relationship to executive functioning following frontal lobe excisions. Brain 2001;124:600-16.
74. Teicher MH, Dumont NL, Ito Y, et al. Childhood neglect is associated with reduced corpus callosum area. Biol Psychiatry 2004;56:80-5.
75. Elberger AJ, Deng J. Corpus callosum and visual cortex of mice with deletion of the NMDA-NR1 receptor: I. Accelerated development of callosal projection neurons. Brain Res Dev Brain Res 2003; 144:121-33.
76. Dapretto M, Davies MS, Pfeifer JH, et al. Understanding emotions in others: mirror neuron dysfunction in children with autism spectrum disorders. Nat Neurosci 2006;9:28-30.
77. Hebb DO. The organization of behavior; a neuropsychological theory. New York: Wiley; 1949:xix, 335 p.
78. Bliss TV, Lomo T. Plasticity in a monosynaptic cortical pathway. J Physiol 1970;207:61P.
79. Collingridge GL, Kehl SJ, McLennan H. Excitatory amino acids in synaptic transmission in the Schaffer collateral-commissural pathway of the rat hippocampus. J Physiol 1983;334:33-46.
80. LeVay S, Wiesel TN, Hubel DH. The development of ocular dominance columns in normal and visually deprived monkeys. J Comp Neurol 1980;191:1-51.
81. Wiesel TN, Hubel DH. Single-Cell Responses in Striate Cortex of Kittens Deprived of Vision in One Eye. J Neurophysiol 1963;26:1003-17.
82. Fox K, Daw N, Sato H, et al. Dark-rearing delays the loss of NMDA-receptor function in kitten visual cortex. Nature 1991;350:342-4.
83. Javitt DC. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry. 2004;9:984-97,979.
84. Rowland LM, Astur RS, Jung RE, et al. Selective cognitive impairments associated with NMDA receptor blockade in humans. Neuropsychopharmacology 2005;30:633-9.
85. Flohr H. An Information Processing Theory of Anesthesia. In: Baars BJ, Banks WP, Newman JB. Essential sources in the scientific study of consciousness. Cambridge, Mass.: MIT Press; 2003:901-912.
86. Pawlak V, Schupp BJ, Single FN, et al. Impaired synaptic scaling in mouse hippocampal neurones expressing NMDA receptors with reduced calcium permeability. J Physiol 2005;562:771-83.
87. Philpot BD, Espinosa JS, Bear MF. Evidence for altered NMDA receptor function as a basis for metaplasticity in visual cortex. J Neurosci 2003;23:5583-8.
88. Kawahara H, Kawahara Y, Westerink BH. The role of afferents to the locus coeruleus in the handling stress-induced increase in the release of noradrenaline in the medial prefrontal cortex: a dual-probe microdialysis study in the rat brain. Eur J Pharmacol 2000; 387:279-86.
89. Nihei MK, Desmond NL, McGlothan JL, et al. N-methyl-D-aspartate receptor subunit changes are associated with lead-induced deficits of long-term potentiation and spatial learning. Neuroscience 2000;99:233-42.
90. Coyle JT, Tsai G. The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology (Berl) 2004;174:32-8.
91. Lee FJ, Liu F. Direct interactions between NMDA and D1 receptors: a tale of tails. Biochem Soc Trans 2004;32:1032-6.
92. Ladd CO, Huot RL, Thrivikraman KV, et al. Long-term adaptations in glucocorticoid receptor and mineralocorticoid receptor mRNA and negative feedback on the hypothalamo-pituitary-adrenal axis following neonatal maternal separation. Biol Psychiatry 2004;55:367-75.
93. Mirescu C, Gould E. Stress and adult neurogenesis. Hippocampus 2006;16:233-8.
94. Chrousos GP, Gold PW. The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA 1992;267:1244-52.
95. Bonne O, Grillon C, Vythilingam M, et al. Adaptive and maladaptive psychobiological responses to severe psychological stress: implications for the discovery of novel pharmacotherapy. Neurosci Biobehav Rev 2004;28:65-94.
96. McMahon SD, Grant KE, Compas BE, et al. Stress and psychopathology in children and adolescents: is there evidence of specificity? J Child Psychol Psychiatry 2003;44:107-33.
97. Lee HJ, Choi JS, Brown TH, et al. Amygdalar nmda receptors are critical for the expression of multiple conditioned fear responses. J Neurosci 2001;21:4116-24.
98. Farb C, Aoki C, Milner T, et al. Glutamate immunoreactive terminals in the lateral amygdaloid nucleus: a possible substrate for emotional memory. Brain Res 1992;593:145-58.
99. Minor TR, Hunter AM. Stressor controllability and learned helplessness research in the United States: sensitization and fatigue processes. Integr Physiol Behav Sci 2002;37:44-58.
100. Bredy TW, Grant RJ, Champagne DL, et al. MJ. Maternal care influences neuronal survival in the hippocampus of the rat. Eur J Neurosci 2003;18:2903-9.
101. De Bellis MD, Hall J, Boring AM, et al. A pilot longitudinal study of hippocampal volumes in pediatric maltreatment-related posttraumatic stress disorder. Biol Psychiatry 2001;50:305-9.
102. Lehmann K, Butz M, Teuchert-Noodt G. Offer and demand: proliferation and survival of neurons in the dentate gyrus. Eur J Neurosci 2005;21:3205-16.
103. Schore AN. Affect dysregulation & disorders of the self. 1st ed. New York: W.W. Norton; 2003:266-306.
104. Kling A, Steklis HD. A neural substrate for affiliative behavior in nonhuman primates. Brain Behav Evol 1976;13:216-38.
105. Baron-Cohen S. Mindblindness: an essay on autism and theory of mind. Cambridge, Mass.: MIT Press; 1995:171.
106. Barbas H. Anatomic basis of cognitive-emotional interactions in the primate prefrontal cortex. Neurosci Biobehav Rev 1995;19:499-510.
107. Bohn I, Giertler C, Hauber W. NMDA receptors in the rat orbital prefrontal cortex are involved in guidance of instrumental behaviour under reversal conditions. Cereb Cortex 2003;13:968-76.
108. Palencia CA, Ragozzino ME. The influence of NMDA receptors in the dorsomedial striatum on response reversal learning. Neurobiol Learn Mem 2004;82:81-9.
109. Brunner R, Parzer P, Schmitt R, et al. Dissociative symptoms in schizophrenia: a comparative analysis of patients with borderline personality disorder and healthy controls. Psychopathology 2004;37:281-4.
110. Paris J. Understanding self-mutilation in borderline personality disorder. Harv Rev Psychiatry 2005;13:179-85.
111. Schmahl C, Greffrath W, Baumgartner U, et al. Differential nociceptive deficits in patients with borderline personality disorder and self-injurious behavior: laser-evoked potentials, spatial discrimination of noxious stimuli, and pain ratings. Pain 2004;110:470-9.
112. Olney JW. New insights and new issues in developmental neurotoxicology. Neurotoxicology 2002;23:659-68.
113. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994;51:199-214.
114. Tsai G, Coyle JT. Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 2002;42:165-79.
115. Holcomb HH, Lahti AC, Medoff DR, et al. Sequential regional cerebral blood flow brain scans using PET with H2(15)O demonstrate ketamine actions in CNS dynamically. Neuropsychopharmacology 2001;25:165-72.
116. Carlsson ML. Hypothesis: is infantile autism a hypoglutamatergic disorder? Relevance of glutamate - serotonin interactions for pharmacotherapy. J Neural Transm 1998;105:525-35.
117. Waterhouse L, Fein D, Modahl C. Neurofunctional mechanisms in autism. Psychol Rev 1996;103:457-89.
118. Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex traits: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry 2003;60:1187-92.
119. Sawamoto N, Honda M, Okada T, et al. Expectation of pain enhances responses to nonpainful somatosensory stimulation in the anterior cingulate cortex and parietal operculum/posterior insula: an event-related functional magnetic resonance imaging study. J Neurosci 2000;20:7438-45.
120. Wu MF, Pang ZP, Zhuo M, et al. Prolonged membrane potential depolarization in cingulate pyramidal cells after digit amputation in adult rats. Mol Pain 2005;1:23.
121. Inturrisi CE. The role of N-methyl-D-aspartate (NMDA) receptors in pain and morphine tolerance. Minerva Anestesiol 2005;71:401-3.
122. Etkin A, Pittenger C, Polan HJ, et al. Toward a neurobiology of psychotherapy: basic science and clinical applications. J Neuropsychiatry Clin Neurosci 2005;17:145-58.
123. Grosjean B. From synapse to psychotherapy: the fascinating evolution of neuroscience. Am J Psychother 2005;59:181-97.
124. Pascual-Leone A, Amedi A, Fregni F, et al. The plastic human brain cortex. Annu Rev Neurosci 2005;28:377-401.
125. Matsuoka N, Aigner TG. D-cycloserine, a partial agonist at the glycine site coupled to N-methyl-D-aspartate receptors, improves visual recognition memory in rhesus monkeys. J Pharmacol Exp Ther 1996;278:891-7.
126. Monahan JB, Handelmann GE, Hood WF, et al. D-cycloserine, a positive modulator of the N-methyl-D-aspartate receptor, enhances performance of learning tasks in rats. Pharmacol Biochem Behav 1989;34:649-53.
127. Heresco-Levy U, Javitt DC, Ermilov M, et al. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 1999;56:29-36.
128. Goff DC, Herz L, Posever T, et al. A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology (Berl) 2005; 179:144-50.
129. Tsai G, Yang P, Chung LC, et al. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 1998;44:1081-9.
130. Tsai G, Lane HY, Yang P, et al. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2004;55:452-6.
131. Tsai GE, Falk WE, Gunther J, et al. Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment. Am J Psychiatry 1999;156:467-9.
132. Heresco-Levy U, Kremer I, Javitt DC, et al. Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder. Int J Neuropsychopharmacol 2002;5:301-7.